BLT 0.00% 2.6¢ benitec biopharma limited

hcv still profitable?

  1. 4,015 Posts.
    lightbulb Created with Sketch. 127
    I have previously reported on the sshrna RNAi treatment for HCV that is being developed by Somagenics.

    Patent issues aside, it would appear that Somagenics has delayed its investment in clinical trials because of recent advancements in other drugs. This could be an indicator of BLT's potential position on its HCV program.

    Regardless of recent BLT statements, the new drug combinations, if they continue to prove effective, will greatly eat into the HCV market. This leaves management needing to rethink what its potential share of the market could be. Clearly, Somagenics are having such a re-think.

    Unfortunately, I don't have access to the full article.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.